Keller Rohrback is investigating reports that certain Jeep and Fiat crossovers and SUVs equipped with 2.4-Liter “Tigershark” engines are consuming too much oil, allegedly causing the vehicles to stall, and often at high speeds. If you or someone you know owns or leases one of the vehicles listed below, please contact Keller Rohrback’s automotive litigation team at email@example.com or (800) 776-6044 to discuss your legal rights.
Today, the Tenth Circuit Court of Appeals rejected Defendants’ bid to appeal the district court’s class certification order for a nationwide RICO class in In re EpiPen (Epinephrine Injection, USP) Marketing, Sales Practices and Antitrust Litigation, the multidistrict litigation against Mylan and Pfizer that seeks to hold Defendants accountable for forcing consumers to pay inflated prices for EpiPens. Today’s order allows the class action to move forward toward trial, which is scheduled for April 2021.
Last week, a Washington federal judge granted the City of Seattle’s motion to dismiss the ERISA Industry Committee v City of Seattle case, which challenged the City’s landmark law requiring large hotels to provide access to adequate health care for their employees and the employees’ families. The motion was granted without leave to amend. Our work on this case led to the firm being named one of Law360’s Legal Lions.
Airline information boards in terminals across the world are covered with cancelled and delayed flights, something we would generally dread seeing. Yet, grounded flights and obsolete travel have become part of our new normal, at least for the time being. The $50 billion lifeline to the industry is a gift from taxpayer to shareholder. While it remains pivotal to prop up a vital industry to provide payroll support over bankruptcy, consumers have been left behind in favor of a more “corporate-focused” recovery plan.
Amid the current outbreak of the novel coronavirus 2019, there has been a surge in exploitative marketing efforts by companies seeking to capitalize on the global public health emergency. We have seen a rise in treatment ads claiming to cure or prevent COVID-19 because companies are choosing to capitalize on coronavirus anxiety. To learn more about our COVID-19 false advertising investigation, please click here or contact us at (800) 776-6044.